Go to deals
Healthcare | TMT

HD Clinical Ltd. has been acquired by NEXUS AG

NEXUS AG has acquired HD Clinical Ltd. Through this acquisition, NEXUS has gained a recognized and internationally active team of experts in structured diagnostic reporting and image processing. This will provide new regional access, strengthening its strong European market position in software, particularly for internal medicine.

HD Clinical was founded in 2005 by a group of clinicians to build an electronic clinical record system starting from departmental requirements and delivering management data derived from real-world patient information. This was a departure from the historic top-down approach of electronic patient record (EPR) systems, which were essentially upgraded patient administration systems with ‘one-size-fits-all’ clinical functionality bolted on. For 17 years, HD Clinical has been delivering digital clinical solutions to healthcare organizations around the world. The company’s solutions are used by 146 organizations across the globe, joining up healthcare organizations and hospital departments to improve the patient experience. The HD Clinical approach is designed to capture maximum engagement from clinical teams by meeting their needs and recognizing the specific requirements of each specialty. Their software and hardware are designed by their in-house team in the HD Clinical UK office.

Nexus AG provides innovative software solutions that allow users at healthcare facilities to focus on what really matters. Their goal is to offer all departments in hospitals, psychiatric wards and rehabilitation and residential institutions the best solution to the challenges they face every day.

Oaklins Evelyn Partners, one of Oaklins’ member firms in the UK, acted as lead the advisor to HD Clinical’s shareholders on the sale of the business. After winning a competitive pitch process, the team advised on all aspects of the transaction, from initial buyer research and preparation for sale to the preparation of marketing documents, leading negotiations and buyer meetings, managing due diligence and general project management throughout the deal.

Parties
“The team at Oaklins Evelyn Partners was able to successfully navigate us through what turned out to be an incredibly complex and challenging transaction process. The level of attention, communication and availability exceeded our expectations. The Oaklins team which led the deal was invaluable to us and provided the required support and advice while keeping the momentum of the deal going. Their drive and determination to get the right deal for the shareholders was exceptional. I look forward to working with the team again in the, hopefully, not too distant future.”

Dr Clive Layton

Founder, HD Clinical

Talk to the deal team

Prashant Dhokia

Senior Associate
Cambridge, United Kingdom
Oaklins Evelyn Partners

Related deals

IQGeo Group plc has been acquired by KKR to enhance geospatial software solutions
Private Equity | TMT

IQGeo Group plc has been acquired by KKR to enhance geospatial software solutions

The global investment firm KKR has acquired IQGeo Group plc, a geospatial software developer headquartered in the UK, for US$429.8 million (£333 million).

Learn more
Atech Support Limited has been acquired by iomart Group plc
TMT

Atech Support Limited has been acquired by iomart Group plc

Pelican Capital’s Atech Support Limited has been acquired by iomart Group plc. This acquisition will enable iomart to provide customers with a broader range of top-tier cloud technology and security services and solutions.

Learn more
PanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production
Healthcare

PanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production

PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.

Learn more